Skip to main content
Top
Published in: Tumor Biology 4/2016

01-04-2016 | Original Article

Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma

Authors: Huimin An, Yu Zhu, Huyang Xie, Yidong Liu, Weisi Liu, Qiang Fu, Dingwei Ye, Jiejie Xu

Published in: Tumor Biology | Issue 4/2016

Login to get access

Abstract

On the basis of aberrant interleukin-8 (IL-8) expression, a crucial angiogenesis factor and potential therapeutic target, in clear-cell renal cell carcinoma (ccRCC), this study aims to assess the prognostic significance of IL-8 in ccRCC. This retrospective study enrolled 271 patients who underwent nephrectomy for ccRCC in a single institution. The associations of IL-8 expression with clinical and pathological features were assessed using chi-squared tests. The impact on cancer-specific survival (CSS) and relapse-free survival (RFS) was analyzed using univariable and multivariable Cox regression models. The area under the receiver operating characteristic (ROC) curve (AUC) was used as an index of prognostic performance. Intratumoral IL-8 was found to be significantly elevated in ccRCC tissues compared with peritumor tissue and be predominately localized in the cytoplasm. Moreover, high IL-8 expression was positively correlated with Fuhrman grade (P < 0.001). Multivariate Cox regression analysis identified IL-8 as an independent adverse prognostic factor of CSS (P < 0.001) and RFS (P < 0.001), which could be incorporated into the traditional TNM staging system to improve the prognostic value for CSS and RFS in ccRCC patients. The predictive accuracy of traditional TNM stage model was significantly improved when IL-8 expression was added. Increased expression of IL-8 is a potential independent adverse prognostic biomarker for CSS and RFS in patients with ccRCC after nephrectomy.
Literature
1.
go back to reference Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60:615–21.CrossRefPubMed Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60:615–21.CrossRefPubMed
2.
go back to reference Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010;7:327–38.CrossRefPubMed Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010;7:327–38.CrossRefPubMed
3.
4.
go back to reference Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A. 2001;98:9754–9.CrossRefPubMedPubMedCentral Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A. 2001;98:9754–9.CrossRefPubMedPubMedCentral
5.
go back to reference Malouf GG, Monzon FA, Couturier J, Molinie V, Escudier B, Camparo P, et al. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:4673–84.CrossRef Malouf GG, Monzon FA, Couturier J, Molinie V, Escudier B, Camparo P, et al. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:4673–84.CrossRef
6.
go back to reference Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6:447–58.CrossRefPubMed Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6:447–58.CrossRefPubMed
7.
go back to reference Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70:1063–71.CrossRefPubMedPubMedCentral Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70:1063–71.CrossRefPubMedPubMedCentral
8.
go back to reference Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406:782–7.CrossRefPubMed Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406:782–7.CrossRefPubMed
9.
go back to reference Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992;307:97–101.CrossRefPubMed Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992;307:97–101.CrossRefPubMed
10.
go back to reference Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science. 1991;253:1278–80.CrossRefPubMed Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science. 1991;253:1278–80.CrossRefPubMed
11.
go back to reference Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:6735–41.CrossRef Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:6735–41.CrossRef
12.
go back to reference Abraham RT. Chemokine to the rescue: interleukin-8 mediates resistance to pi3k-pathway-targeted therapy in breast cancer. Cancer Cell. 2012;22:703–5.CrossRefPubMed Abraham RT. Chemokine to the rescue: interleukin-8 mediates resistance to pi3k-pathway-targeted therapy in breast cancer. Cancer Cell. 2012;22:703–5.CrossRefPubMed
13.
go back to reference Chavey C, Muhlbauer M, Bossard C, Freund A, Durand S, Jorgensen C, et al. Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappab pathway in breast cancer. Mol Pharmacol. 2008;74:1359–66.CrossRefPubMed Chavey C, Muhlbauer M, Bossard C, Freund A, Durand S, Jorgensen C, et al. Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappab pathway in breast cancer. Mol Pharmacol. 2008;74:1359–66.CrossRefPubMed
14.
go back to reference Zhang Y, Wang L, Zhang M, Jin M, Bai C, Wang X. Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of egf-egfr-pi3k-akt-erk pathway. J Cell Physiol. 2012;227:35–43.CrossRefPubMed Zhang Y, Wang L, Zhang M, Jin M, Bai C, Wang X. Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of egf-egfr-pi3k-akt-erk pathway. J Cell Physiol. 2012;227:35–43.CrossRefPubMed
15.
go back to reference Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, et al. Nonapical and cytoplasmic expression of interleukin-8, cxcr1, and cxcr2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:4117–27.CrossRef Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, et al. Nonapical and cytoplasmic expression of interleukin-8, cxcr1, and cxcr2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:4117–27.CrossRef
16.
go back to reference Konig B, Steinbach F, Janocha B, Drynda A, Stumm M, Philipp C, et al. The differential expression of proinflammatory cytokines il-6, il-8 and tnf-alpha in renal cell carcinoma. Anticancer Res. 1999;19:1519–24.PubMed Konig B, Steinbach F, Janocha B, Drynda A, Stumm M, Philipp C, et al. The differential expression of proinflammatory cytokines il-6, il-8 and tnf-alpha in renal cell carcinoma. Anticancer Res. 1999;19:1519–24.PubMed
17.
go back to reference Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of cxcr2/cxcr2 ligand biological axis in renal cell carcinoma. J Immunol. 2005;175:5351–7.CrossRefPubMed Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of cxcr2/cxcr2 ligand biological axis in renal cell carcinoma. J Immunol. 2005;175:5351–7.CrossRefPubMed
18.
go back to reference Grepin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, et al. The cxcl7/cxcr1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res. 2014;74:873–83.CrossRefPubMed Grepin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, et al. The cxcl7/cxcr1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res. 2014;74:873–83.CrossRefPubMed
19.
go back to reference Inozume T, Hanada K, Wang QJ, Yang JC. Il-17 secreted by tumor reactive t cells induces il-8 release by human renal cancer cells. J Immunother. 2009;32:109–17.CrossRefPubMed Inozume T, Hanada K, Wang QJ, Yang JC. Il-17 secreted by tumor reactive t cells induces il-8 release by human renal cancer cells. J Immunother. 2009;32:109–17.CrossRefPubMed
20.
go back to reference Takamori H, Oades ZG, Hoch OC, Burger M, Schraufstatter IU. Autocrine growth effect of il-8 and groalpha on a human pancreatic cancer cell line, capan-1. Pancreas. 2000;21:52–6.CrossRefPubMed Takamori H, Oades ZG, Hoch OC, Burger M, Schraufstatter IU. Autocrine growth effect of il-8 and groalpha on a human pancreatic cancer cell line, capan-1. Pancreas. 2000;21:52–6.CrossRefPubMed
21.
go back to reference Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine. 2000;12:78–85.CrossRefPubMed Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine. 2000;12:78–85.CrossRefPubMed
22.
go back to reference Lang K, Niggemann B, Zanker KS, Entschladen F. Signal processing in migrating t24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop. Int J Cancer. 2002;99:673–80.CrossRefPubMed Lang K, Niggemann B, Zanker KS, Entschladen F. Signal processing in migrating t24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop. Int J Cancer. 2002;99:673–80.CrossRefPubMed
23.
go back to reference Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer. 2007;121:1949–57.CrossRefPubMed Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer. 2007;121:1949–57.CrossRefPubMed
24.
go back to reference Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, et al. Hif-1 and nf-kappab-mediated upregulation of cxcr1 and cxcr2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene. 2007;26:7333–45.CrossRefPubMed Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, et al. Hif-1 and nf-kappab-mediated upregulation of cxcr1 and cxcr2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene. 2007;26:7333–45.CrossRefPubMed
25.
go back to reference Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, et al. Fully humanized neutralizing antibodies to interleukin-8 (abx-il8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;161:125–34.CrossRefPubMedPubMedCentral Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, et al. Fully humanized neutralizing antibodies to interleukin-8 (abx-il8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;161:125–34.CrossRefPubMedPubMedCentral
26.
go back to reference Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5:3711–21. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5:3711–21.
27.
go back to reference Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappab. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9:3167–75. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappab. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9:3167–75.
28.
go back to reference Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol. 2001;158:735–43.CrossRefPubMedPubMedCentral Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol. 2001;158:735–43.CrossRefPubMedPubMedCentral
Metadata
Title
Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma
Authors
Huimin An
Yu Zhu
Huyang Xie
Yidong Liu
Weisi Liu
Qiang Fu
Dingwei Ye
Jiejie Xu
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4158-8

Other articles of this Issue 4/2016

Tumor Biology 4/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine